Orchard Therapeutics has licensed lentiviral stable cell line technology from GlaxoSmithKline for use in its hematopoietic stem cell gene therapies.

GSK filed for patents on the technology before selling its rare disease gene therapy portfolio to Orchard in 2018.

The deal sets Orchard up to use the technology in the production of its gene therapies for Wiskott Aldrich syndrome and transfusion-dependent beta thalassemia. Source: Fierce Biotech 15/7/2020